Accueil
PRES LYON
Nous contacter
Archives
WebAdminUnités de recherche
Partenaire 15: Centre de Recherche en Neurosciences de Lyon
Biologie, médecine, santé
- Adresse :
- -Centre de Recherche en Neurosciences de Lyon (équipe BioRaN) Université Lyon 1 - CNRS UMR5292 - INSERM U1028 -CERMEP - Imagerie du Vivant Groupement Hospitalier Est, Hôpitaux de Lyon
- Sur Internet :
- http://crnl.univ-lyon1.fr/index.php/fr
- Tutelle :
- UCBL UJM - CNRS - INSERM - HCL
Organisation
Représentant: Luc ZIMMER
The team BioRaN aims at developing biochemical and radiopharmaceutical biomarkers directed toward similar brain targets and providing complementary information. There is increasing evidence that biomarkers can help answer key questions that arise during the exploration of pathophysiological processes, the diagnostic of a disease or the drug development process. Such biomarkers fall into two broad categories. The first group are biochemical, such as levels of amyloid-β (Aβ)42 peptide and tau in cerebrospinal fluid (CSF). The second are based on imaging technologies, including positron emission tomography (PET) imaging of amyloid or of receptors, and magnetic resonance imaging (MRI) of structural changes. The use of imaging biomarkers for the assessment of drug therapies –a field termed here as “pharmaco-imaging”- has become more common in recent years. Not surprisingly, the rise in use of pharmaco-imaging methodologies coincided with the technical advances that occurred in medical imaging, especially in the non-invasive in vivo imaging modalities such as MRI and PET. Neuroimaging techniques like PET have been developed that provide evidence for Aβ deposition and receptor neurodegeneration already at early clinical disease stages. Theoretically, a biomarker would serve as a surrogate end point if it reflects clinically relevant outcomes such as cognitive decline. Nevertheless, an imaging marker could be used as a primary pre-specified outcome measure in a proof-of-concept study if the imaging marker reflects an underlying disease process. Therefore, imaging markers may be used to assess the presumed mechanism of action of a new compound in proof-of-concept studies. Moreover, imaging studies can lead to unexpected findings that help to critically evaluate primary assumptions on the pathophysiology or on mode of action of new compounds. In this context the main objectives of the team are i) to find and develop PET radiopharmaceuticals and biochemical assays as biomarkers in order to validate therapeutic targets in animal models and patients. In drug discovery and development, biomarkers should facilitate selection of drug candidates, verify the mechanism of action, define dose effects and enable clinical trials to be shortened and run with reduced sample size; ii) to propose to clinicians innovative strategies to facilitate differential diagnostics. Biomarkers should serve as diagnostic tools in clinical practice to allow early and presymptomatic identification of patients and to aid treatment decisions and monitoring in individualized care. For example, the efficacy of current drugs for Alzheimer's disease is assessed in patients clinically diagnosed with symptomatic Alzheimer's disease.
Axe(s) de recherche
Created in Jan. 2011, the Lyon Neuroscience Research Center (INSERM, CNRS, University Lyon1, University Saint Etienne) integrates the multidisciplinary expertise of 11 teams (350 members including 200 permanent researchers, faculty, clinician‐researchers, and support staff) making possible a synergistic approach on integrative and cognitive neurophysiology and related brain disorders. The neural and molecular substrates of brain functions, from sensory and motor processes to cognition and mind, are investigated along two entwined strategic directions: from gene and cell to behavior, and from bench to bedside.
